Drugs / BCX17725
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06539507 | Sep 2024 → Oct 2026 expected | Netherton syndrome | BioCryst Pharmaceuticals | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-05-05 | BioCryst Pharmaceuticals | Regulatory BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update biocryst.com ↗
U.S. IND open for BCX17725 for Netherton syndrome |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-05-05 | BioCryst Pharmaceuticals | BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update biocryst.com ↗ |
| 2024-10-02 | BioCryst Pharmaceuticals | BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome biocryst.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCX17725 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06539507 ↗ |
| Route | Intravenous | “BCX17725 when administered via multiple IV and/or SC doses through 12 weeks” NCT06539507 ↗ |
| Route | Subcutaneous | “BCX17725 when administered via multiple IV and/or SC doses through 12 weeks” NCT06539507 ↗ |